Family Medicine Doctors in Coraopolis, PA Accepting Medicare

4 Family Medicine doctors found. Showing 1 - 4

Mr. Iyalla Ned Adoki, MD Family Medicine - Adult Medicine Medicare: Accepting Medicare Assignments Practice Location: 1104 Fifth Avenue, Coraopolis, PA 15108 Phone: 412-262-3455    Fax: 412-262-3415

Dr. Samina Naseer, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1308 5th Ave, Coraopolis, PA 15108 Phone: 412-262-4694    Fax: 412-262-5920

Renee Rubinstein, MD Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 170 Old Beaver Grade Rd, Coraopolis, PA 15108 Phone: 412-788-4447    Fax: 412-788-4443

Alecia Renee Hutsler, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 900 Hiland Ave, Coraopolis, PA 15108 Phone: 412-865-7839

News Archive

Tioga Pharmaceuticals announces commencement of asimadoline Phase 2 study for treatment of pruritus

Tioga Pharmaceuticals, a clinical stage biotechnology company, today announced the initiation of a Phase 2 clinical study of asimadoline, a novel, well-studied kappa-opioid receptor specific agonist, for the treatment of pruritus or itching. The double-blind, placebo-controlled clinical study is designed to evaluate the safety, tolerability, and clinical efficacy of asimadoline in patients with pruritus due to atopic dermatitis and is being conducted at 20 clinical study centers in the United States.

State roundup: Colorado uninsured/underinsured rate skyrockets; Georgia personhood resolution brewing

The Colorado Health Access Survey, a new report from The Colorado Trust and the Colorado Health Institute, has found that more than 1.5 million Coloradans – or nearly one in three residents – either have no health insurance or are underinsured, meaning they spend more than 10 percent of their income on out-of-pocket medical expenses. Just since the last survey two years ago, the percentage of employers offering health insurance has dropped to 57.8 percent this year from 63.7.

FDA provides QIDP designation to Debiopharm's Debio 1450 for treatment of ABSSSI

Debiopharm Group™(Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs including anti-infective and oncology therapeutics as well as companion diagnostics, today announced that the US Food and Drug Administration (FDA) has designated its anti-infectious agent Debio 1450 as a Qualified Infectious Disease Product (QIDP) for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

Scientists receive $2 million NIH grant to improve orthopedic surgery using biomimetic patch

Two Washington University in St. Louis scientists are imitating nature as they attempt to solve one of the most difficult problems in orthopedic surgery: reattaching tendon to bone.

Plexxikon commences dosing in PLX4032 Phase 3 trial for metastatic melanoma

Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors. The randomized, controlled, Phase 3 "BRAF Inhibitor in Melanoma" (BRIM3) trial in previously untreated patients is part of the planned registration program for PLX4032.

Read more Medical News

› Verified 6 days ago